BNP对CRT后期疗效的临床评价

Clinical Evaluation of BNP in Treatment of Late CRT

目的观察B-型脑钠肽(brain natriuretic peptide,BNP)对心脏再同步化起搏器治疗慢性心功能不全(chronic heart failure,CHF)的临床评价。方法选择2010年3月~2017年1月于我院顺利完成心脏再同步化治疗的慢性心功能不全患者46例。在治疗前及治疗后6个月,对患者进行NYHA分级标准评估,通过采取心脏超声来对相应患者的LVEF(左室射血分数),LVESVI(左室收缩末期容量指数)相关指数进行评价,并且采取酶联免疫法(Enzyme-linked immunosorbent assay,ELISA)测定研究对象手术前后BNP的表达水平,随后运用统计学软件分析检验结果。结果终点观察达到6个月,研究对象LVEF,LVESVI及心脏功能NYHA分级标准均较治疗前明显表达上调,且有统计学差异(P<0.05);患者BNP的浓度较治疗前显著降低,且有统计学差异(P<0.05)。结论 CRT明显改善慢性心衰的心功能,通过检测患者BNP水平可对其做出有效评价。

Objective To observe the clinical evaluation of B-brain natriuretic peptide(BNP)in the treatment of chronic cardiac insufficiency(chronic heart failure)with cardiac cardiac(cardiac resynchronization therapy).Methods From March 2010~2017 year in January in our hospital,the successful completion of cardiac resynchronization therapy of the patients with chronic heart failure in 46 cases.In 6 months before and after treatment,the patients were evaluated by NYHA grading standards,LVEF(LVEF)and LVESVI(relative index of left ventricular end-systolic index)of the corresponding patients were evaluated by using echocardiography.Enzymelinked immunosorbent assay(ELISA)BNP expression level before and after surgery,and then use the statistical software analysis of test results.Results The end point of observation reached 6 months,the study objects LVEF,LVESVI and cardiac function NYHA grade were significantly higher than the treatment of expression,and there was a significant difference(<0.05);patients with BNP concentrations were significantly lower than before treatment,and statistically difference(<0.05).Conclusion CRT significantly improves cardiac function in patients with chronic heart failure,which can be effectively assessed by measuring BNP levels in patients.